Vortioxetine hydrobromide troban Identification and characterization of small

Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor

8-tetramethyl-3

CN1C2NC=NC=2C(=O)N(C)C1=O

Preclinical studies reveal that KW-2449 is converted by monoamine oxidase-B (MAO-B) and aldehyde oxidase into its major metabolite M1

and leads to down-regulation of STAT3 phosphorylation

Vortioxetine hydrobromide troban Identification and characterization of smallVortioxetine, also known as Lu AA21004, is an atypical antidepressant, and was approved in 2013 by the U. S. FDA for the treatment of major depressive disorder (MDD) in adults. Vortioxetine is a so called "serotonin modulator and stimulator." It has been shown to possess the following pharmacological actions: Serotonin transporter (SERT) blocker (i. e. serotonin reuptake inhibitor (SRI)) Ki (binding affinity) = 1. 6 nM, IC50 = 5. 4 nM; Norepinephrine